Concepedia

Reduced FcεRI-Mediated Release of Asthma-Promoting Cytokines and Chemokines from Human Basophils during Omalizumab Therapy

Janet M. Oliver, Christy A. Tarleton, Laura Gilmartin, Tereassa Archibeque, Clifford Qualls, Lorena Diehl, Bridget S. Wilson, Mark Schuyler

International Archives of Allergy and Immunology · 2009 · 58 citations · 33 references

DOIFull text

Open access

Abstract

Omalizumab may reduce asthma symptoms in part by suppressing the FcepsilonRI-mediated production by basophils of Th2 cytokines and selected chemokines. Anti-IgE-stimulated basophil cytokine synthesis appears more sensitive than histamine release to the loss of FcepsilonRI caused by omalizumab treatment.

References

33

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

William W. Busse, Jonathan Corren, Bobby Q. Lanier et al. · Journal of Allergy and Clinical Immunology · 2001 · 1.3K citations · Full text

, , +9

A mechanism for the initiation of allergen-induced T helper type 2 responses

Caroline L. Sokol, Gregory M. Barton, Andrew G. Farr et al. · Nature Immunology · 2007 · 936 citations · Full text

, , +10

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

M. Solèr, Jonathan Matz, Robert G. Townley et al. · European Respiratory Journal · 2001 · 822 citations · Full text

Down-regulation of Fc(ε)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody

Donald W. MacGlashan, Bruce S. Bochner, D C Adelman et al. · The Journal of Immunology · 1997 · 818 citations · Full text

The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects.

John V. Fahy, Hannah Fleming, Hofer Wong et al. · American Journal of Respiratory and Critical Care Medicine · 1997 · 714 citations

, , +14